Current treatment of intrahepatic cholangiocarcinoma (ICC) remains ineffective because knowledge of ICC carcinogenesis is unclear. Increasing evidence suggests that microRNAs (miRNAs), including miR-191, play an important role in tumorigenesis; but expression and biological functions of miR-191 in ICC remain to be established. This study investigated the functions and underlying mechanisms of miR-191 in ICC. ICC miRNA profiles were generated in five pairs of ICC and matched to normal bile duct tissues by next-generation sequencing technology; ICC miRNA profiles were verified in 18 pairs of ICC tissues and normal bile duct tissues by quantitative RT-PCR. The miR-191-associated mechanisms in ICC were investigated in vitro and in vivo, and clinical outcomes associated with miR-191 were correlated in 84 patients. Our results showed that miR-191 expression was significantly increased in ICC compared with the adjacent normal bile duct tissues (P < 0.001). Overexpression of miR-191 promoted proliferation, invasion, and migration of cholangiocarcinoma cells in vitro and in vivo. The elevated miR-191 expression reduced the expression level of ten-eleven translocation 1 (TET1)-a direct target gene of miR-191 in ICC, which catalyzes demethylation. The reduced TET1 expression level allowed the methylated CpG-rich regions at the p53 gene transcription start site stay methylated, leading to reduced p53 expression level, which compromises p53's anticancer vigor. Finally, miR-191 was found to be an independent risk factor for poor prognosis in patients with ICC (overall survival, hazard ratio 5 3.742, 95% confidence interval 2.080-6.733, P < 0.001; disease-free survival, hazard ratio 5 2.331, 95% confidence interval 1.346-4.037, P 5 0.003). Conclusion: Our results suggest that overexpressed miR-191 is associated with ICC progression through the miR-191/TET1/p53 pathway. (HEPATOLOGY 2017;66:136-151).
I ntrahepatic cholangiocarcinoma (ICC) accounts for 5%-10% of primary liver cancers.
(1) Several molecular mechanisms in ICC have been proposed. (2, 3) Furthermore, recently it has been suggested that microRNAs (miRNAs) are key players in ICC pathogenesis. (4) Indeed, miRNAs play an important role in regulating cell proliferation, differentiation, apoptosis, invasion, and migration in various cancers. By profiling miRNA expression in ICC tissues, we may illustrate the involvement of miRNAs in ICC carcinogenesis. miR-191 is up-regulated in some solid tumors including colorectal cancer, breast cancer, and hepatocellular carcinoma. (5) (6) (7) The target genes of miR-191 differ among different solid tumors. For instance, they target SATB1 in human breast cancer, (5) b-catenin in lung cancer, (8) and cyclin-dependent kinase 6 (CDK6) in thyroid follicular tumors. (9) However, no study has investigated the target genes of miR-191 in ICC.
Tumor growth and cancer invasiveness are generally controlled by epigenetic events, (10, 11) including aberrant DNA methylation, such as hypermethylation localized in CpG islands of the targeted genes, leading to inactivation of specific tumor-suppressor genes (TSGs). (12) It has been reported that DNA methylation is involved in the pathogenesis of cholangiocarcinoma. (13) Recent studies also indicate that DNA demethylation can be catalyzed by a class of methylcytosine dioxygenases from the ten-eleven translocation (TET) family. (14, 15) TET1 promotes DNA demethylation by primarily catalyzing conversion of 5-methylcytosine to 5-hydroxymethylcytosine as well as 5-formylcytosine or 5-carboxylcytosine. (15, 16) TET1 has been recently identified as a tumor suppressor in many cancers including gastric, colorectal, liver, lung, (17) breast, prostate, and pancreatic cancers. (18) (19) (20) Moreover, TET1 suppresses cancer invasion by activating tissue inhibitor of metalloproteinases 2 and 3 in prostate and breast cancer according to the study by Hsu et al. (18) Recently, TET1 has been shown to suppress breast tumor growth, invasion, and metastasis by up-regulating the homeobox A genes HOXA7 and HOXA9. (21) However, no reports have investigated the association between TET1 and ICC.
p53 is a potent tumor suppressor, known as the "guardian of the genome." (22) Kulis and Esteller reported that p53 inactivation was the most common dysfunction (observed in 37% of ICCs). (12) Only one report, by Fu et al., described the association of TET1 with p53. (23) It showed that TET1 overexpression induced p53 tumor suppressor protein in gastric cancer. We wanted to know whether regulation of p53 by TET1 is mediated through demethylation in ICC.
The objectives of the current study were to investigate miR-191 expression in ICC, to identify a main target gene of miR-191 in ICC, and to evaluate the biological impact of the interactions between miR-191 and the target gene on ICC cell behaviors. The ultimate goal was to clarify molecular pathways that promote cell proliferation, migration, invasion, and metastasis of ICC.
Thus, in conclusion, our study showed that miR-191 inhibits ICC apoptosis; facilitates ICC proliferation, invasion, and metastasis; and functions as a biomarker for predicting the prognosis of ICC. We also determined that miR-191 negatively regulates TET1, which is bound to the transcription start site (TSS) of p53 where expression of p53 is positively regulated through demethylation of p53 in cholangiocarcinoma cells. This newly discovered pathway (miR-191/ TET1/p53) may be critical in ICC progression and metastasis, and knowledge of this pathway may assist in the development of a novel strategy for treating ICC. 
Materials and Methods

PATIENTS AND SPECIMENS
CELL CULTURE
Human cholangiocarcinoma cell lines (HuCCT1 and QBC939) were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). QBC939 derives from an extrahepatic cholangiocarcinoma, which has a short proliferation cycle and is easy to culture. HuCCT1 is a human intrahepatic cholangiocellular carcinoma cell line and represents a moderately differentiated adenocarcinoma. It also has a short proliferation cycle and is easy to culture. Both cells function as standard cell lines for in vitro ICC study. We expected the two cell lines to behave similarly, and thus, both cell lines were used to corroborate the results in this study. Normal human intrahepatic bile duct epithelial cells (HIBECs) were supplied by ScienCell Research Laboratories (San Diego, CA). HIBECs were derived from two normal human donors and cryopreserved. HuCCT1 and HIBEC cells were cultured in Roswell Park Memorial Institute 1640 medium, while QBC939 cells were cultured in Dulbecco's modified Eagle's medium; both media were supplemented with 10% fetal bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA) and 1% penicillin-streptomycin.
SMALL RNA LIBRARY PREPARATION AND NEXT-GENERATION SEQUENCING
Small RNA libraries were prepared using a TruSeq Small RNA Sample Preparation Kit (Illumina, San Diego, CA) with multiplexing capability. Following the procedure in the TruSeq Kit user guide, the total RNA containing the small RNA fractions were ligated to 5 0 and 3 0 adaptors sequentially before conversion to complementary DNA (cDNA) by reversetranscription followed by PCR amplification with unique index sequences primers.
The quality of cDNA was assessed using a highly sensitive DNA chip (Agilent Technologies, Santa Clara, CA). Index sequences consist of six-base indices to distinguish different samples in a single lane of a flow cell that used the Illumina multiplexing capability. Finally, the samples were pooled and subjected to a 6% (wt/vol) nondenaturing polyacrylamide gel electrophoresis run. Then, cDNA fragments (between 145 and 160 bp from the corresponding miRNA libraries) were excised from the gel, purified, and eluted. The final cDNA pellet was air-dried and resuspended in 10 mL nuclease-free water, and the quantity of the cDNA libraries was measured using a Qubit fluorometer.
All final libraries were then pooled at a final concentration of 2 nM and sequenced in two flow cells in Illumina's platform HiSeq run. Prior to sequencing, the small RNA libraries were again validated using another DNA chip. The sequencing reads have been deposited at the National Center for Biotechnology Information Gene Expression Omnibus with accession number GSE93366.
Other assays used in this study are described in the Supporting Information.
STATISTICAL ANALYSIS
The normalized microarray data are available at the National Center for Biotechnology Information's Gene Expression Omnibus (accession GSE93366). The differential expression of miRNA was analyzed by Student t test. The difference in the detected miRNAs was considered significant when P < 0.05 and log 2 (fold change) >1 or <-1. All statistical analyses were performed using SPSS v22.0 software (IBM SPSS, Chicago, IL). Differences between two groups were assessed using Student t test. The association between miR-191 and TET1 protein expression in ICC tissues was analyzed using Spearman's correlation. Overall survival and disease-free survival were estimated using the Kaplan-Meier method, and the difference in survival was evaluated using the log-rank test. P < 0.05 indicated statistical significance.
Results
miRNA EXPRESSION PROFILE VARIED BETWEEN ICC AND ADJACENT NORMAL INTRAHEPATIC BILE DUCT TISSUE
To investigate the miRNA expression profile in ICC, next-generation miRNA sequencing was performed using RNA isolated from five pairs of ICC and their adjacent normal intrahepatic bile duct tissues. A total of 1,643 miRNAs were identified. Among them, miR-191 was up-regulated in tumor tissues, compared with the adjacent normal bile duct tissues (the expression profiles of some miRNAs are shown in Fig. 1A ). Because the expression and possible carcinogenic involvement of miR-191 in cholangiocarcinoma remain unknown, we decided to focus on miR-191 in our experiments. First, 18 pairs of tissues were selected to verify the expression level of miR-191 using quantitative RT-PCR. Consistent with the miRNA sequencing analysis (P < 0.001), miR-191 was significantly up-regulated in ICC tissues compared with the matched adjacent normal bile duct tissues (P < 0.001) (Fig. 1B) . In addition, miR-191 expression was higher in cholangiocarcinoma cells (QBC939 and HuCCT1 cells) than in normal HIBECs (P < 0.01) (Fig. 1C) .
CpG methylation can suppress gene expression, as shown by He et al. who reported that methylation of miR-191 coding gene in hepatocellular carcinoma negatively impacted the expression of miR-191. (24) miR-191 expression level is likely determined by methylation in the CpG regions of the miR-191 coding sequence. We analyzed the extent of methylation status in the miR-191 coding sequence. The unmethylation rate in the miR-191 coding sequence was higher in cholangiocarcinoma cells (HuCCT1 cells and QBC939 cells) than in normal bile duct epithelial cells (HIBECs). Similarly, the unmethylation rate was significantly higher in cholangiocarcinoma tissues than in adjacent normal bile duct tissues (75.7% versus 22.5%, P < 0.01) (Fig. 1D) . (Fig. 2C ). These findings suggest that miR-191 may promote cholangiocarcinoma cell proliferation by accelerating cell cycles.
Several cell cycle regulators including cyclin D1, cyclin B1, p27, and p21 were also affected by miR-191. Cyclin D1 and cyclin B1 were up-regulated, whereas p27 and p21 were down-regulated, by miR-191 mimic in cholangiocarcinoma cells at both the mRNA and protein levels. In contrast to miR-191 mimic, the miR-191 inhibitor promoted p27 and p21 expression and reduced the expression of cyclin D1 and cyclin B1 (Supporting Fig. S2 ).
Next, we sought additional evidence that miR-191 promotes cholangiocarcinoma cell proliferation. We transfected normal cells (HIBECs) with miR-191 mimics. CCK8 analysis found that overexpression of miR-191 in HIBECs significantly increased cell proliferation after 4 days (Fig. 2D) . Epithelial-mesenchymal transition (EMT) is a process through which epithelial cells lose the epithelial phenotype as well as cell-cell contacts and morphologically transit to mesenchymal cells. EMT is characterized by down-regulation of Ecadherin expression and up-regulation of N-cadherin expression. (25) Overexpression of miR-191 in HIBECs exhibited a significant EMT change as observed at day 4, including the loss of E-cadherin expression and a gain of N-cadherin expression (Fig. 2E, left) . Moreover, there were significant differences in the expression of these genes between miR-191 mimics and control groups (P < 0.001; Fig. 2E right) 
miR-191 PROMOTED THE INVASION AND MIGRATION OF CHOLANGIOCARCINOMA CELLS IN VITRO
To determine the effect of miR-191 on cholangiocarcinoma cell invasion/migration, we performed Transwell Matrigel invasion and a wound-healing assay. Transwell Matrigel cell invasion assay revealed that overexpression of miR-191 in QBC939 and HuCCT1 cells significantly promoted their ability to invade the Matrigel chamber compared with control cells (Fig. 3A, left) .
Knockdown of miR-191 significantly reduced the invasion ability of QBC939 and HuCCT1 cells compared with the control groups (Fig. 3A, right) . Additionally, a cell wound healing assay was performed to investigate the effect of miR-191 on cell migration. The migration ability of QBC939 and HuCCT1 cells with miR-191 overexpression was enhanced compared with control cells (Fig. 3B, left) . Knockdown of miR-191 decreased the migration ability of QBC939 and HuCCT1 cells compared to the miR-control groups (Fig. 3B, right) .
Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that can enzymatically break down connective tissues, are thought to be a factor in tumor invasion and metastasis. (26) More importantly, MMPs are closely associated with miR-191-targeted TET1. (18) Therefore, in our study, we analyzed the expression of MMP-2 and MMP-9. miR-191 overexpression significantly enhanced the expression of MMP-2 and MMP-9 in QBC939 and HuCCT1 cells compared with control cells (Fig. 3C) . Knockdown of miR-191 significantly reduced the expression of MMP-2 and MMP-9 in QBC939 and HuCCT1 cells compared with control (Fig. 3C ).
miR-191 INHIBITED THE APOPTOSIS OF CHOLANGIOCARCINOMA CELLS TREATED BY CISPLATIN IN VITRO
Knockdown of miR-191 increased the number of apoptotic QBC939 and HuCCT1 cells compared with control cells (Supporting Fig. S3A ; P < 0.05). Given the very small number of apoptotic cells detected among the miR-191-transfected cells and control cells, despite the significant P value, we decided to seek clearer evidence on the apoptosis of cells upon the coexpression of miR-191. We used cisplatin (which is recommended as a frontline chemotherapy drug for cholangiocarcinoma) to toxicate QBC939 and HuCCT1 cells. Apoptotic QBC939 and HuCCT1 cells were significantly increased after cisplatin treatment (Supporting Fig. S3B) .
miR-191 mimic-transfected cells showed resistance to cisplatin treatment and reduced the number of apoptotic cells compared with control cells (Fig. 3D) . Knockdown of miR-191 sensitized the cells to cisplatin and increased the number of apoptotic cells compared with control cells (Fig. 3D) .
Apoptosis progression uses specific cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP), which facilitates cellular disassembly and serves as a marker of apoptosis. With cisplatin treatment, western blotting showed that overexpression of miR-191 reduced cleaved PARP and that knockdown of miR-191 increased cleaved PARP (Fig. 3D) . (Fig. 4A) . Compared to control mice, the average tumor volume was significantly larger in mice inoculated with miR-191-transfected QBC939 cells at the fourth week ( Fig. 4B, left ; P < 0.001). However, the implanted cells with low expression of miR-191 grew more slowly than the control (Fig. 4A) .
miR-191 PROMOTED TUMOR GROWTH AND METASTASIS
Average tumor volume was significantly smaller in mice inoculated with Lv-anti-miR-191-transfected QBC939 cells at the fourth week than in control mice ( Fig. 4B, left ; P < 0.01). Tumor weights (Fig. 4B , right) were also lower in transfected mice.
Ki-67, a proliferation marker, was stained on xenograft specimens. Ki-67-positive staining was significantly more frequent in tumors formed from miR-191-transfected QBC939 cells than that in control cells. Compared to control cells, there were significantly fewer cells with Ki-67-positive staining in tumors formed from Lv-anti-miR-191-transfected QBC939 cells (Fig. 4C, left) .
Overexpression of MMP9 and MMP2 was observed in tumors formed from miR-191-transfected QBC939 cells compared with control cells. Low expression of MMP9 and MMP2 was observed in tumors formed from Lv-anti-miR-191-transfected QBC939 cells compared with control cells (Fig. 4C,  right) .
In addition, we used the in situ intrahepatic cholangiocarcinoma model to study tumor metastasis. After 14 days, all mice were measured by bioluminescence imaging (BLI). The BLI intensity in liver, lung, and other areas was quantitatively detected. But our focus was the remote metastasis that requires the transportation of fallen cancer cells through blood or lymphatic vessels (lung metastasis is a good example of remote metastasis).
The BLI signal showed that tumors formed from miR-191-transfected QBC939 cells were more likely to metastasize to the lungs (average BLI intensity of 1.2 3 10 8 photons/second/cm 2 /sr versus 4310 7 photons/second/cm 2 /sr; P < 0.01) in vivo than the control (Fig. 4D) . Five mice (100%, 5/5) with lung metastasis were implanted with miR-191-transfected QBC939 cells; only one mouse (20%, 1/5) with lung metastasis in the control groups was similarly implanted. No mice with lung metastasis were implanted with the miR-191 Lv-anti-miR-191-transfected QBC939 cells (Supporting Fig. S4 ; P > 0.05), thus suggesting that knockdown of miR-191 in QBC939 cells inhibited metastasis to the lung.
miR-191 REGULATED TET1 EXPRESSION LEVEL
The miR-191 in QBC939 and HuCCT1 cells was overexpressed in order to investigate whether TET1 was a target of miR-191. Indeed, TET1 protein expression dramatically decreased in cells overexpressing miR-191, whereas inhibition of miR-191 up-regulated TET1 expression (Fig. 5A) .
Previous studies have shown that several genes (such as SATB1, CDK6, and b-catenin) are negatively regulated by miR-191 in human cancers. (5, 8, 9) However, we did not detect any changes in the expression levels of these proteins in QBC939 cells transfected with an miR-191 mimic and HuCCT1 cells transfected with an miR-191 inhibitor (Supporting Fig. S5) .
We further used an algorithm (miRWalk) developed by Dweep et al. (27) to identify miR-191 targets in cholangiocarcinoma. The algorithm miRWalk consists of a comprehensive miRNA database, which can be used to predict and validate miRNA binding sites on all known genes of human, mouse, and rat species. All mRNAs, mitochondrial genes, and 10-kb upstream flanking regions of all known genes of human, mouse, and rat can be analyzed by miRWalk, a newly developed algorithm with eight established programs for putative miRNA binding sites.
Among all suggested targets, the TET1 gene harbors a potential miR-191 binding site in its 3 0 -untranslated region (UTR) (Supporting Fig. S6 ). To verify whether the 3 0 -UTR of TET1 mRNA was a functional target of miR-191, a luciferase reporter gene assay was performed. The 3 0 -UTR sequence of TET1 (wild-type 3 0 -UTR) was cloned into a luciferase reporter vector (Fig. 5B) . Luciferase activity was significantly down-regulated by the miR-191 mimics.
Conversely, luciferase activity was significantly upregulated by the miR-191 inhibitor. Furthermore, we mutated the binding motif bases for miR-191 within the TET1 3 0 -UTR and found that both mimics and inhibitors of miR-191 exerted no effect on luciferase (E) Incidence of lung metastasis among the different groups of nude mice. Hematoxylin and eosin-stained images of lung tissues harvested. ***P < 0.001, **P < 0.01, *P < 0.05.
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HEPATOLOGY, July 2017 activity (Fig. 5C ). These findings indicate a direct interaction between miR-191 and TET1 mRNA. All subcutaneous tumor tissues were divided into two parts: one lysed for protein analysis and the other paraffin-embedded for immunohistochemistry. Western blot and immunohistochemical staining techniques and analyses revealed lower TET1 expression in the miR-191-overexpressing tumors than in the negative controls (Fig. 5D,E) . Western blot analysis and immunohistochemical staining also revealed higher TET1 expression levels in the Lv-anti-miR-191 tumors than in the control group (Fig. 5D,E) . Western blot analysis and immunohistochemical staining showed that expression levels of the TET1 protein were decreased in ICC tissues compared with the adjacent normal bile duct tissues (Fig. 5F ). Similar patterns were demonstrated by in situ hybridization. Expression of miR-191 inversely correlated with TET1 expression (P < 0.01) (Fig. 5G) .
QBC939 and HuCCT1 cells were cotransfected with miR-191 mimics and TET1 expression plasmids to further determine whether miR-191-induced cholangiocarcinoma cell proliferation, invasion, and migration can be ascribed to TET1. Overexpression of miR-191 enhanced cell viability, proliferation, invasion, and migration; but these changes were significantly suppressed by restoration of TET1 expression (Fig. 6A-D) .
FIG. 6.
Restoration of TET1 attenuated miR-191-induced cholangiocarcinoma cell proliferation, invasion, and migration. Cell proliferation (B), invasion (C), and migration (D) were measured by the cotransfected miR-191 mimics and TET1 plasmids (A). ***P < 0.001, **P < 0.01, *P < 0.05. Abbreviations: BrdU, bromodeoxyuridine; Ctrl, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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TET1 DIRECTLY BOUND TO CpG-RICH REGIONS OF THE p53 GENE, PROMOTED p53 DEMETHYLATION, AND POSITIVELY REGULATED p53 EXPRESSION
To determine possible impacts of a changed level of TET1 expression on p53 level, we increased the intracellular levels of miR-191 expression in QBC939 cells bearing wild-type p53 gene (Supporting Table S1 ). TET1 and p53 protein expression levels significantly reduced. In contrast, the miR-191 inhibitor enhanced TET1 and p53 protein expression levels (Fig. 7A) .
To investigate the relationship between TET1 and p53, we transfected the TET1 plasmid into QBC939 cells. TET1 overexpression increased the mRNA and protein expression levels of p53 and p53 target genes (i.e., BAX and GADD45) in QBC939 cells. Transfection of small interfering RNA TET1 decreased the mRNA and protein expression levels of p53 and p53 target genes of BAX and GADD45 in QBC939 cells ( Fig. 7B; Supporting Fig. S7A,B) .
Furthermore, we explored whether TET1 directly or indirectly regulated p53 in cholangiocarcinoma cells using a coimmunoprecipitation (co-IP) assay. In co-IP analysis, input and immunoglobulin G (IgG) served as positive and negative controls, respectively. The reciprocal co-IP analysis revealed that endogenous TET1 interacted directly with p53 in QBC939 cells (Fig. 7C) .
To investigate potential binding site of TET1 in p53, we conducted a chromatin immunoprecipitation assay. TET1 was enriched with CpG islands at the TSS of the target genes. We examined whether TET1 directly regulated p53 expression by binding to their CpG islands. Four sites that contain CpG islands from an approximately 2-kb region upstream and a 2-kb region downstream of the p53 promoter were selected. Normal rabbit IgG was used as a negative control. Pull-down with the specific TET1 antibody identified the PCR fragments containing four CpG islands in p53. Chromatin immunoprecipitation-quantitative PCR assay confirmed that TET1 bound to the site-4 region of the p53 TSS in QBC939 (Fig. 7D left) . No interaction with the negative control (IgG) was observed. Amplified DNA bands were isolated from the agarose gel, and the p53 sequence was verified by sequencing in QBC939 cells (Fig. 7D right) .
Luciferase reporter assay was performed to clarify whether TET1 up-regulated p53 at the transcriptional level. The site-4 sequence of the p53 gene located in the TSS was inserted upstream of the p53 promoter. Luciferase reporter gene assay and western blot analysis showed that TET1 activated p53 expression in a dosedependent manner in QBC939 cells (Fig. 7E) .
We subsequently investigated whether TET1 demethylates the p53 gene. Bisulfite sequencing analysis showed that TET1 transfection significantly increased the demethylation of the TSS of p53 in QBC939 cells compared with controls (68.0% versus 33.0%; Fig. 7F ). These results suggested that TET1 bound directly to the TSS location of p53 for demethylation in the binding region.
ELEVATED miR-191 EXPRESSION WAS ASSOCIATED WITH POORER SURVIVAL OF PATIENTS WITH ICC
To determine the clinical significance of miR-191, we performed survival analysis in 84 patients with ICC. Baseline characteristics of the patients are listed in Supporting Table S2 . Patients were divided into two groups based on their miR-191 expression levels. miR-191 expression levels positively correlated with tumor-node-metastasis stages in patients with ICC. Patients with high miR-191 expression in tumors displayed a more advanced disease state (stages 3 and 4) than patients with low expression of miR-191 in tumors (27.3% versus 7.5%, P < 0.01).
Patients with high miR-191 expression in tumors displayed shorter overall survival and disease-free survival than patients with low miR-191 expression (P < 0.001 and P 5 0.002, respectively) (Fig. 8A) . Multivariate analysis showed that miR-191 was predictive of overall survival (hazard ratio 5 3.742, 95% confidence interval 2.080-6.733, P < 0.001) and disease-free survival (hazard ratio 5 2.331, 95% confidence interval 1.346-4.037, P 5 0.003) of patients (Supporting Table  S3 ). Moreover, pairwise comparisons indicated that patients with low miR-191 (negative) and high TET1 (positive) expression levels had significantly improved overall survival and disease-free survival compared to patients with high miR-191 (positive) and low TET1 (negative) expression (Fig. 8B) . These findings suggest that a combination of two variables can improve the prediction of outcomes in patients with ICC.
Discussion
To be efficient in selecting a likely candidate for further investigation, we applied several levels of screening Chromatin immunoprecipitationquantitative PCR analysis showed that TET1 bound to the CpG islands in the TSS domain of p53. Normal rabbit IgG was used as a negative control. Amplified DNA bands were isolated from the agarose gel, and the p53 sequence was verified by sequencing. (E) TET1 transactivated p53 promoter activities. The p53 promoter in the luciferase expression construct that contains site 4 was cotransfected with TET1, and promoter activities were detected using a luciferase reporter assay. Western blot analysis of p53 expression in QBC939 cells with increasing doses of the transfected TET1 plasmid. (F) Methylation of TSS of p53 in QBC939 cells transfected with TET1 plasmid was measured by bisulfite modification sequencing. ***P < 0.001, **P < 0.01. Abbreviations: CHIP, chromatin immunoprecipitation; EV, empty vector; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitation; NC, negative control; siRNA, small interfering RNA. steps to eliminate unlikely candidates: (1) the altered expression must be verified by RT-PCR in additional ICC samples, (2) the miRNAs with verified altered expression must show detectable function in facilitating ICC cell proliferation, and (3) they must show a predictive value using the receiver operating characteristic curve. After several rounds of elimination, miR-191 appeared to be one of the likely candidates with strong association with ICC. The sensitivity and specificity of miR-191 in predicting ICC were impressive with a 70% area under the curve (data not shown). These analyses gave us confidence that miR-191 was one of the miRNAs for ICC pathogenesis.
This study analyzed the biological functions and molecular mechanisms of miR-191 in ICC. Several new findings were discovered. First, miR-191, a protumor regulator, was unmethylated and up-regulated in a subset of human ICC and cholangiocarcinoma cell lines, thereby inhibiting cancer cell apoptosis and promoting cancer cell proliferation, invasion, and metastasis in vitro and in vivo. Second, overexpression of miR-191 in normal bile duct epithelial cells (HIBECs) increased not only cell proliferation but also EMT. EMT is a process that is involved in transforming normal epithelial cells to malignant cells. It enhances cell infiltration and metastasis during the process of malignant evolution. (25) Overexpression of miR-191 promotes EMT in HIBECs, suggesting that miR-191 promotes the transformation of normal bile duct epithelial cells to cholangiocarcinoma cells. Third, TET1 was identified as an miR-191 target gene that could bind to the TSS of the p53 gene, which positively regulated the expression of the p53 protein because of demethlyation of the p53 TSS. Fourth, miR-191 could be used as a biomarker to predict prognosis in patients with ICC. A combination of miR-191 with TET1 resulted in a more accurate prediction.
Consistent with findings that miR-191 is upregulated in some solid tumors, (5) (6) (7) 28) we found that miR-191 was up-regulated in ICC, thereby inhibiting cell apoptosis and promoting cell proliferation, invasion, and metastasis. Zhang et al. researched differences in miRNA expression profiles between ICC and normal intrahepatic bile ducts; however, no significant difference in miR-191 expression was found between the two groups. (29) The different findings between Zhang et al. and our own study may be due to samples being paraffin-embedded tissues and freshly frozen tissues (which better preserve the RNA contents for more efficient extraction), respectively. miR-191 was an independent risk factor for overall survival and disease-free survival in this cohort. High expression levels of miR-191 in tumor tissues were associated with advanced ICC, and overall survival and disease-free survival were reduced in such patients compared to those with low expression levels of miR-191 in tumor tissues. These findings indicate that miR-191 could be used as a biomarker for ICC progression and that a combination of miR-191 with TET1 may be better for predicting overall survival and disease-free survival. In addition, we are exploring whether detection of serum miR-191 may have clinical value for early diagnosis and postoperative follow-up. We used the Gene Expression Omnibus database (GSE59856) to analyze the miR-191 level in the serum of 98 patients with cholangiocarcinoma and 150 healthy controls. We found that the miR-191 level in the serum of cholangiocarcinoma patients was significantly higher than that in healthy controls (data not shown), which was encouraging. Clearly, more effort and participation are required to advance this goal.
The underlying mechanisms of miR-191 in promoting cholangiocarcinoma growth in vitro and in vivo were also investigated. miR-191 down-regulated the expression of two cyclin-dependent kinase inhibitors, p21 and p27, but up-regulated the expression of cyclin D1 and cyclin B1. As a result, the transition of the cell cycle from G 0 /G 1 phase to S phase was accelerated. MMPs are enzymes implicated in tumor metastasis, up-regulation of MMP expression, enhanced tumor cell invasion, and metastasis. (30) miR-191 up-regulated the expression of MMP2 and MMP9. This is consistent with a report showing how miR-191 enhanced the metastasis of colorectal carcinoma by up-regulating the expression levels of MMP2 and MMP9. (6) miR-191 reportedly targets SATB1 in human breast cancer, (5) CDK6 in thyroid follicular tumors, (9) and beta-catenin in lung cancer. (8) However, changes in expression levels of SATB1, CDK6, and beta-catenin were not associated with elevated miR-191 levels in this study. In searching for additional target genes, we determined that TET1 was likely one of the genes targeted by miR-191 because the 3 0 -UTR of TET1 contains complementary matches to the seed sequence of miR-191. We subsequently validated this target relationship between miR-191 and TET1.
Our results suggest that target genes of miR-191 could be tissue-specific as they differ according to cancer type. It is conceivable that there are more genes regulated by miR-191 in ICC that can be further explored in future study. TET1 was recently identified as a tumor suppressor in gastric, colorectal, liver, lung, breast, prostate, and pancreatic cancers. (17) (18) (19) 23) Moreover, TET1 down-regulation is associated with invasion and metastasis of breast and colon cancers. (21, 31) Hypermethylation of a specific TSG can be detrimental to anticancer activity, and TET1 promotes DNA demethylation of TSGs for increased TSG-mediated anticancer vigor. (12, 24, (32) (33) (34) p53 is a potent tumor suppressor, known as "the guardian of the genome." (22) Methylation of p53 plays a vital role in liver cancer growth, and p53 is the most common tumor suppressor in ICC. (35, 36) We found that TET1 directly bound the TSS of the p53 gene and positively regulated p53 expression by demethylating the CpG islands of the TSS in the p53 gene. The elevated miR-191 level negatively regulated TET1, thus reducing the binding of TET1 to the p53 gene and allowing the p53 gene to remain methylated in cholangiocarcinoma (Fig. 8C) . We realize that p53 may represent only one TET1 target gene because TET1 (in theory) may also regulate methylation status in other genes. We expect to identify additional target genes of TET1 in ICC in another study.
Our data highlight the pivotal role played by (elevated expression of) miR-191 in apoptosis, proliferation, invasion, and metastatic behaviors of cholangiocarcinoma cells. Data also suggest that miR-191 may function as a new biomarker for predicting poor outcomes for patients with ICC.
